Johnson & Johnson (JNJ) : 10-15 Associates reduced its stake in Johnson & Johnson by 17.0% during the most recent quarter end. The investment management company now holds a total of 104,131 shares of Johnson & Johnson which is valued at $11.8 Million after selling 21,329 shares in Johnson & Johnson , the firm said in a disclosure report filed with the SEC on May 25, 2016.Johnson & Johnson makes up approximately 3.58% of 10-15 Associates’s portfolio.
Other Hedge Funds, Including , Whalerock Point Partners boosted its stake in JNJ in the latest quarter, The investment management firm added 110 additional shares and now holds a total of 50,594 shares of Johnson & Johnson which is valued at $5.7 Million. Johnson & Johnson makes up approx 2.43% of Whalerock Point Partners’s portfolio.Landmark Financial Advisors reduced its stake in JNJ by selling 216 shares or 9.88% in the most recent quarter. The Hedge Fund company now holds 1,970 shares of JNJ which is valued at $221,901. Johnson & Johnson makes up approx 0.23% of Landmark Financial Advisors’s portfolio.Colonial Trust Advisors reduced its stake in JNJ by selling 1,888 shares or 1.7% in the most recent quarter. The Hedge Fund company now holds 109,064 shares of JNJ which is valued at $12.4 Million. Johnson & Johnson makes up approx 4.09% of Colonial Trust Advisors’s portfolio. Diamond Hill Capital Management Inc added JNJ to its portfolio by purchasing 1,969 company shares during the most recent quarter which is valued at $223,600.Pegasus Partners Ltd. reduced its stake in JNJ by selling 1,270 shares or 5.79% in the most recent quarter. The Hedge Fund company now holds 20,650 shares of JNJ which is valued at $2.3 Million. Johnson & Johnson makes up approx 1.29% of Pegasus Partners Ltd.’s portfolio.
Johnson & Johnson opened for trading at $112.57 and hit $113.06 on the upside on Wednesday, eventually ending the session at $112.78, with a gain of 0.08% or 0.09 points. The heightened volatility saw the trading volume jump to 47,49,563 shares. Company has a market cap of $310,218 M.
On the company’s financial health, Johnson & Johnson reported $1.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Apr 19, 2016. Analyst had a consensus of $1.65. The company had revenue of $17482.00 million for the quarter, compared to analysts expectations of $17491.02 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 EPS.
Many Wall Street Analysts have commented on Johnson & Johnson. Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.Company shares were Reiterated by RBC Capital Mkts on Apr 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 125 from a previous price target of $122 .Company shares were Reiterated by Piper Jaffray on Apr 20, 2016 to “Neutral”, Firm has raised the Price Target to $ 106 from a previous price target of $105 .
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.